Lexaria Bioscience (LEXX) EBITDA (2017 - 2026)

Lexaria Bioscience has disclosed EBITDA across 10 years of filings, most recently posting -$1.4 million for Q1 2026.

• EBITDA for Q1 2026 came in at -$1.4 million, up 49.11% year-over-year; the trailing twelve-month figure through Feb 2026 was -$9.5 million (changed 0.15% YoY), and the FY2025 annual result was -$12.0 million, down 105.54% from the prior year.
• EBITDA came in at -$1.4 million for Q1 2026 at Lexaria Bioscience, up from -$1.6 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of -$674537.0 in Q1 2024 to a low of -$3.8 million in Q2 2025.
• The 5-year median for EBITDA is -$1.8 million (2022), against an average of -$1.9 million.
• Across the five-year window, EBITDA plunged 316.35% in 2025 and jumped 49.11% in 2026, its largest moves.
• Lexaria Bioscience's EBITDA stood at -$1.8 million in 2022, then soared by 33.09% to -$1.2 million in 2023, then sank by 130.38% to -$2.7 million in 2024, then jumped by 40.86% to -$1.6 million in 2025, then rose by 10.71% to -$1.4 million in 2026.
• The last three EBITDA figures came in at -$1.4 million (Q1 2026), -$1.6 million (Q4 2025), and -$2.7 million (Q3 2025), per Business Quant data.